Patient P-03365
Therapy response
Declining
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
74%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 39 NP-02 recommended — Dietary Support Protocol NP-02
- Day 40 Patient accepted — Started NP-02 in the companion
- Day 50 GI symptom burden −22% vs expected — Dietary Support Protocol NP-02
- Day 56 Tolerance state changed — Unstable → Improving
- Day 58 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 81 ME-01 recommended — Monitoring Escalation ME-01
- Day 82 Patient accepted — Started ME-01 in the companion
- Day 85 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 58.
Primary contributors, last 14 days
- Treatment adherence-26
- GI instability-15
- Inflammatory activity-10
- Toxicity-7
- Nutritional resilience+6
What helped?
- Dietary Support Protocol NP-02Day 39Result: symptom burden −22%
- Monitoring Escalation ME-01Day 81Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
81%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 82% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 43
- WearableHRV 23 ms, trending down
- Drug metabolism and exposure ↑20
- BloodToxicity index 43
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 1.8 · butyrate capacity 38/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 25 ms
- Sleep
- 6.9 h
- Steps
- 5,318
- Resting HR
- 69 bpm
Daily log: GI score 42, nutritional resilience 49, adherence 60.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03204 | 25% | S16 | AD-05 | improved | 48 |
| P-03482 | 25% | S05 | AD-05 | no change | 67 |
| P-03105 | 24% | S12 | AD-05 | no change | 60 |
| P-03351 | 24% | S07 | AD-05 | no change | 51 |
| P-03111 | 23% | S07 | AD-05 | no change | 48 |
| P-03187 | 22% | S12 | AD-05 | no change | 80 |
| P-03380 | 22% | S16 | AD-05 | improved | 34 |
| P-03424 | 22% | S12 | AD-05 | improved | 41 |
| P-03441 | 22% | S19 | AD-05 | improved | 37 |
| P-03034 | 21% | S14 | AD-05 | no change | 30 |
| P-03129 | 21% | S18 | AD-05 | no change | 32 |
| P-03208 | 22% | S02 | BR-03 | improved | 57 |